Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novartis to divest Proleukin’s US rights to Clinigen for $210m

pharmaceutical-technologyFebruary 14, 2019

Tag: Novartis , Proleukin , Protein , melanoma

PharmaSources Customer Service